First Drugs That Could Be Picked For Price Negotiation Showcase Longevity Of Some Brands
Executive Summary
The first drugs expected to face US Medicare drug price negotiations, according to a new analysis, will have had an average commercial life span of 15 years.
You may also be interested in...
Tracking Industry’s Lawsuits Against IRA’s Medicare Price Negotiations
Industry stakeholders have filed various lawsuits against the US government, attempting to slow down or block the implementation of a new Medicare drug price negotiation program. Pink Sheet's new chart tracks the developments.
Tracking Industry’s Lawsuits Against IRA’s Medicare Price Negotiations
Industry stakeholders have filed various lawsuits against the US government, attempting to slow down or block the implementation of a new Medicare drug price negotiation program. Scrip's new chart tracks the developments.
AbbVie Wary Of IRA Potential Impact On Struggling Imbruvica
While AbbVie tries to estimate which of its products might fall into CMS price negotiations, it is seeing lower-than-expected sales erosion for Humira and continued growth for Skyrizi and Rinvoq.